GlobalData has reviewed global clinical trials in immuno-oncology (IO) for 2008–2017: they increased at a 17% Compound Annual Growth Rate (CAGR) over the 10-year period.
For the purposes of this analysis, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively. Overall, Phase II trials outnumbered all other trials by contributing between 52% and 62% across the period, or 57% on average.
Go deeper with GlobalData
The share of Phase I trials remained at around 31% across the 10-year period, as shown in Figure 1.
Phase III trials’ contribution ranged between 7% and 12%, or 9% on average, whereas Phase IV trials’ share remained flat at approximately 3%.
This shows the fast pace IO features with regard to the development of new drugs. It also highlights the relatively early stage the field is in, considering that 88% of the trials are in Phase II or below.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
